Abstract:

SGLT2 inhibitors, originally approved for type 2 diabetes mellitus, have demonstrated efficacy in reducing cardiovascular events, particularly heart failure, in patients with and without diabetes. An intriguing research area involves exploring the potential application of SGLT2 inhibitors in cardio-oncology, aiming to mitigate the cardiovascular adverse events associated with anticancer treatments. These inhibitors present a unique dual nature, offering both cardioprotective effects and anticancer properties, conferring a double benefit for cardio-oncology patients. This review first examines the established cardioprotective effects of SGLT2 inhibitors in heart failure and subsequently explores the existing body of evidence, including both preclinical and clinical studies, that supports the use of SGLT2 inhibitors in the context of cardio-oncology. This review further discusses the mechanisms through which SGLT2 inhibitors protect against cardiovascular toxicity secondary to cancer treatment. Finally, it explores the potential anticancer effects of SGLT2 inhibitors along with their proposed mechanisms.

JACC CardioOncology Editor-in-Chief and CME Editor
Bonnie Ky, MD, MSCE, FACC

Authors
Mohammed S. Dabour, MS

Anne H. Blaes, MD, MS

Beshay N. Zordoky, MS, PhD

Important Dates

Date of Release: April 16, 2024
Term of Approval/Date of CME/MOC Expiration: April 15, 2025